Huons Probiotic 'Menolacto' Obtains Patent for Core Ingredient YT1 Improving Vaginal Dryness

Huons' 'Menolacto Premium'
Photo by Huons

Huons announced on the 23rd that it has obtained a domestic patent for the prevention and improvement effects of 'Lactobacillus acidophilus YT1' on vaginal dryness.

This patent is the third composition technology that expands the scope of rights for the prevention and improvement of individual symptoms of female menopause using YT1. Following two composition patents registered in 2021 for the improvement and prevention of individual menopausal symptoms such as numbness in hands and feet, palpitations, formication, insomnia, and dizziness, Huons has further enhanced the technological value of YT1 by acquiring a technology patent for the improvement and prevention of vaginal dryness.

YT1 is the core ingredient of 'Menolacto,' a probiotic for female menopause. It is a new material technology transferred in 2017 from the Korea Food Research Institute, a government-funded research institute under the Ministry of Science and ICT, and was recognized in 2019 by the Ministry of Food and Drug Safety as an individually acknowledged ingredient for improving menopausal symptoms. Menolacto has maintained steady sales through various distribution channels since its launch. After recording sales of 17.5 billion KRW in its first year, it achieved 40 billion KRW in 2021 and 42 billion KRW last year, surpassing a cumulative sales of 100 billion KRW over three years.

A Huons representative said, “As the first domestic menopausal probiotic YT1 has acquired additional technology patents for menopausal symptoms, its technological value has been further enhanced. Having proven solid quality, we will expand touchpoints with customers to increase competitiveness.”